ClinicalTrials.gg
CompletedNCT03042273Updated Mar 18, 2020

High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection

A Phase 2 interventional study of High Strength Cranberry and Placebo in Urinary Tract Infection, sponsored by Swisse Wellness Pty Ltd. Completed at 5 sites in Australia. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Swisse Wellness Pty Ltd · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This clinical trial is a Phase 2, multicenter, placebo-controlled, double-blind, parallel-arm study to evaluate the efficacy and safety of High Strength Cranberry (500mg Pacran®) in preventing UTI (cystitis) in women with a history of recurrent UTI (rUTI).

02

Conditions studied

  • Urinary Tract Infection

Keywords

  • recurrent
03

In context

Urinary Tract Infections

803 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

This study's enrollment of 150 is above the median of 131 across 560 interventional studies indexed under Urinary Tract Infections.

Browse Urinary Tract Infections studies →

Lead sponsor

Swisse Wellness Pty Ltd is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged 18-65 years, inclusive
  2. A history of recurrent urinary tract infection defined as ≥3 UTIs in the last year OR at least 2 UTIs occurring in the last 6 months. Each infection requires confirmation by a health professional
  3. Willing to answer questionnaires and comply with the study requirements
  4. Ability to swallow capsules
  5. Provided Written
  6. >17.5kg m2 and \<35kg m2

Exclusion criteria

Exclusion Criteria:

  1. Microbial growth on urine culture of ≥107 cfu/L (104cfu/mL) within 7 days of Day 1
  2. A history of >5 UTIs in the last 6 months (confirmed by self-report or health professional)
  3. Use of antibiotics or antibiotics for prophylaxis within 28 days of Day 1
  4. Use of any antibacterial products, that in the opinion of the Medical Investigator may interfere with the study outcomes, within 28 days of Day 1
  5. Regular use of Vaccinium containing products (e.g. all forms of blueberries, cranberries, bilberry, lingonberry , etc i.e fruit, dried fruit, pills, juices or supplements) within 28 days of Day 1 at the discretion of the Medical Investigator
  6. Presence of an intermittent or indwelling urinary catheter
  7. Anatomical abnormalities of the urinary tract
  8. History of or known renal or urological disease(self-reported)
  9. Positive urine dipstick pregnancy test at screening onDay 1, currently pregnant and/or breastfeeding
  10. Women of not willing to use adequate and effective methods of throughout the study
  11. Women of child bearing potential that have not been using effective methods of contraception for 14 days prior to Day 1
  12. History of or known clinically significant cardiac disease
  13. History of or known clinically significant liver disease
  14. History of or known clinically significant gastrointestinal disease
  15. History of or known metabolic disorder or diabetes
  16. History or presence of alcohol or illicit drug abuse,any surgical history, clinical condition or organ dysfunction that in the opinion of the Medical Investigator may affect the participant's ability to participate in the study or the study results
  17. Currently hospitalised or any planned hospitalisations within 1 month following the last dose of study product
  18. participants or participants receiving immunosuppressive medication
  19. History of an adverse reaction or known or suspected allergy to the product ingredients
  20. Currently taking warfarin or has received Warfarin within 28 days of Day 1
  21. Received an investigational drug within 28 days of Day 1
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    High Strength Cranberry

    1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months

    Dietary Supplement: High Strength Cranberry

  • Placebo comparator
    Placebo

    1 capsule of Matching Placebo orally daily for 6 months

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementHigh Strength Cranberry

    Softgel capsule

    Also known as: 25,000mg Vaccinium macrocarpon

  • Dietary supplementPlacebo

    Soy oil to match High Strength Cranberry Softgel Capsule

    Also known as: Placebo (for High Strength Cranberry)

06

What researchers measure

Primary outcomes

  1. Incidence of UTI

    cultured confirmed UTIs at a level of \>108cfu/L (105cfu/mL)

    Time frame: 6 months

07

Study locations

5 sites
  • Holdsworth House Medical Centre
    Sydney, New South Wales 2010, Australia
  • Holdsworth House Medical Centre
    Brisbane, Queensland 4006, Australia
  • Griffith University Clinical Trial Unit (Griffith Health)
    Gold Coast, Queensland 4222, Australia
  • CSIRO Nutrition and Health Research Clinic
    Adelaide, South Australia, Australia
  • Monash Alfred Psychiatry Research Centre (MAPrc)
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03042273
Lead sponsor
Swisse Wellness Pty Ltd
Collaborators
Commonwealth Scientific and Industrial Research Organisation, Australia
Responsible party
Sponsor
First posted
Feb 3, 2017
Start date
May 15, 2017
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Mar 18, 2020

Study contacts

Welma Stonehouse, PhD
principal investigator · Commonwealth Scientific and Industrial Research Organisation, Australia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion